Subscribe To Our Free Newsletter |
Shilpa Medicare rises after marketing partner launches pemetrexed formulation in US
Shilpa Medicare advanced 1.61% to Rs 549.15 after the company informed that its marketing partner, Amneal Pharmaceuticals, has launched 'PEMRYDI RTU' (Pemetrexed injection), a ready-to-use pemetrexed formulation, in the US market.